Unnamed: 0,title,date,stock,sentiment
955823.0,"Oncolytics shares are trading higher after the company presented clinical proof-of-concept data from its phase 1b study in carfilzomib-refractory multiple myeloma patients at ASCO. UPDATE: Shares have since reversed, now lower.",2020-05-29 08:49:00-04:00,ONCY,positive
955824.0,"The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant",2020-05-29 07:22:00-04:00,ONCY,positive
955825.0,Oncolytics Highlights Presentation Of Clinical Proof-Of-Concept Data In Multiple Myeloma At ASCO,2020-05-29 07:10:00-04:00,ONCY,neutral
955826.0,65 Biggest Movers From Yesterday,2020-05-29 05:35:00-04:00,ONCY,neutral
955827.0,48 Stocks Moving In Thursday's Mid-Day Session,2020-05-28 12:28:00-04:00,ONCY,neutral
955828.0,28 Stocks Moving in Thursday's Pre-Market Session,2020-05-28 07:34:00-04:00,ONCY,neutral
955829.0,70 Biggest Movers From Yesterday,2020-05-28 06:09:00-04:00,ONCY,neutral
955830.0,58 Stocks Moving In Wednesday's Mid-Day Session,2020-05-27 12:19:00-04:00,ONCY,neutral
955831.0,Oncolytics Biotech Presents Clinical Data 'Supporting a Predictive Biomarker of Pelareorep Response in Breast Cancer' At ESMO Breast Cancer Virtual Meeting,2020-05-26 07:09:00-04:00,ONCY,negative
955832.0,The Week Ahead In Biotech: ASCO Presentations In The Spotlight,2020-05-24 14:40:00-04:00,ONCY,neutral
955833.0,30 Stocks Moving in Friday's Pre-Market Session,2020-05-22 07:18:00-04:00,ONCY,neutral
955834.0,82 Biggest Movers From Yesterday,2020-05-19 04:44:00-04:00,ONCY,neutral
955835.0,"The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Earnings Flow Slows",2020-05-17 12:30:00-04:00,ONCY,positive
955836.0,Oncolytics Reports Publication Of Abstracts For ASCO,2020-05-14 07:17:00-04:00,ONCY,neutral
955837.0,"RBC Capital Maintains Outperform on Oncolytics Biotech, Lowers Price Target to $6",2020-05-11 08:17:00-04:00,ONCY,negative
955838.0,Oncolytics Biotech Q1 EPS $0.010 Down From $0.040 YoY,2020-05-08 07:11:00-04:00,ONCY,neutral
955839.0,Oncolytics Biotech To Present Clinical Findings Of Pelareorep-Induced Immune Response In Breast Tumors At The ESMO Breast Cancer Virtual Meeting,2020-05-04 07:07:00-04:00,ONCY,negative
955840.0,Oncolytics Biotech Highlights Publication Of Pelareorep's Clinical Benefit Against KRAS-Mutated Colorectal Cancer,2020-04-02 07:08:00-04:00,ONCY,negative
955841.0,"Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus package boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.",2020-03-27 10:58:00-04:00,ONCY,positive
955842.0,Oncolytics Biotech Granted US Patent Titled 'Reoviruses having modified sequences',2020-03-24 10:17:00-04:00,ONCY,positive
955843.0,Shares of several companies in the healthcare space are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.,2020-03-16 10:18:00-04:00,ONCY,negative
955844.0,20 Healthcare Stocks Moving In Monday's Pre-Market Session,2020-03-16 08:32:00-04:00,ONCY,neutral
955845.0,Shares of several healthcare  companies are trading lower. Movement appears market-related as markets continue to dip amid the global coronavirus outbreak and OPEC failing to reach production agreement.,2020-03-09 10:55:00-04:00,ONCY,neutral
955846.0,100 Biggest Movers From Friday,2020-03-09 05:25:00-04:00,ONCY,neutral
955847.0,Shares of several healthcare companies are trading lower. Movement appears market related as markets continue to dip amid the global coronavirus outbreak.,2020-03-06 09:11:00-05:00,ONCY,neutral
955848.0,101 Biggest Movers From Yesterday,2020-03-06 04:28:00-05:00,ONCY,neutral
955849.0,Oncolytics Biotech Says Had $14.1M In Cash And Cash Equivalents As Of Dec. 31,2020-03-05 16:02:00-05:00,ONCY,neutral
955850.0,108 Biggest Movers From Yesterday,2020-03-03 04:57:00-05:00,ONCY,neutral
955851.0,Shares of several healthcare companies are trading lower as the global coronavirus spread continues to cause equities across sectors to sell off amid worsened economic outlook.,2020-02-28 09:06:00-05:00,ONCY,negative
955852.0,94 Biggest Movers From Friday,2020-02-24 04:53:00-05:00,ONCY,neutral
955853.0,35 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2020-02-18 08:25:00-05:00,ONCY,neutral
955854.0,Shares of several healthcare companies are trading higher in sympathy with the overall market after China reported the lowest number of new coronavirus cases since late January.,2020-02-12 11:05:00-05:00,ONCY,positive
955855.0,85 Biggest Movers From Yesterday,2020-02-04 04:56:00-05:00,ONCY,neutral
955856.0,61 Stocks Moving In Monday's Mid-Day Session,2020-02-03 12:25:00-05:00,ONCY,neutral
955857.0,Shares of several healthcare companies are trading higher in sympathy with the overall market on a rebound after increased fear of the Wuhan coronavirus' impact on the economy dropped the Dow roughly 600 points on Friday.,2020-02-03 11:13:00-05:00,ONCY,positive
955858.0,54 Stocks Moving In Friday's Mid-Day Session,2020-01-31 12:17:00-05:00,ONCY,neutral
955859.0,90 Biggest Movers From Yesterday,2020-01-30 04:15:00-05:00,ONCY,neutral
955860.0,62 Stocks Moving In Tuesday's Mid-Day Session,2020-01-29 12:25:00-05:00,ONCY,neutral
955861.0,Oncolytics Biotech shares are trading lower. Not seeing any company-specific news to justify the price action.,2020-01-29 11:11:00-05:00,ONCY,neutral
955862.0,20 Healthcare Stocks Moving In Monday's Pre-Market Session,2020-01-27 07:40:00-05:00,ONCY,neutral
955863.0,14 Biotechnology Stocks Moving In Monday's Pre-Market Session,2020-01-27 07:38:00-05:00,ONCY,neutral
955864.0,146 Biotechnology Stocks Moving In Thursday's Session,2020-01-23 12:47:00-05:00,ONCY,neutral
955865.0,26 Biotechnology Stocks Moving In Wednesday's After-Market Session,2020-01-22 23:28:00-05:00,ONCY,neutral
955866.0,36 Healthcare Stocks Moving In Wednesday's After-Market Session,2020-01-22 23:23:00-05:00,ONCY,neutral
955867.0,82 Biggest Movers From Yesterday,2020-01-22 04:18:00-05:00,ONCY,neutral
955868.0,20 Biotechnology Stocks Moving In Tuesday's After-Market Session,2020-01-21 23:35:00-05:00,ONCY,neutral
955869.0,29 Healthcare Stocks Moving In Tuesday's After-Market Session,2020-01-21 23:28:00-05:00,ONCY,neutral
955870.0,34 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-01-15 08:10:00-05:00,ONCY,neutral
955871.0,80 Biggest Movers From Yesterday,2020-01-15 04:48:00-05:00,ONCY,neutral
955872.0,85 Biggest Movers From Yesterday,2020-01-14 04:52:00-05:00,ONCY,neutral
955873.0,50 Biggest Movers From Yesterday,2020-01-07 04:19:00-05:00,ONCY,neutral
955874.0,30 Stocks Moving In Monday's Mid-Day Session,2020-01-06 12:39:00-05:00,ONCY,neutral
955875.0,Oncolytics Biotech shares are trading higher. Not seeing any company-specific news to justify the price action.,2020-01-06 10:26:00-05:00,ONCY,positive
955876.0,65 Biggest Movers From Yesterday,2020-01-03 04:36:00-05:00,ONCY,neutral
955877.0,42 Stocks Moving In Thursday's Mid-Day Session,2020-01-02 12:13:00-05:00,ONCY,neutral
955878.0,Mid-Day Market Update: Dow Rises 170 Points; Synthesis Energy Systems Shares Jump,2020-01-02 12:05:00-05:00,ONCY,positive
955879.0,Oncolytics biotech shares are trading lower as a potential sell-off after the stock increased roughly 185% over the last 5 trading sessions.,2020-01-02 11:49:00-05:00,ONCY,positive
955880.0,"The Daily Biotech Pulse: Canadian Approval For Amarin's Vascepa, Innate Pharma's Blood Cancer Drug Accepted For Review In Europe",2020-01-02 08:46:00-05:00,ONCY,negative
955881.0,63 Biggest Movers From Tuesday,2020-01-02 05:05:00-05:00,ONCY,neutral
955882.0,Mid-Afternoon Market Update: Dow Falls 40 Points; Core Laboratories Shares Slide,2019-12-31 14:25:00-05:00,ONCY,positive
955883.0,38 Stocks Moving In Tuesday's Mid-Day Session,2019-12-31 12:18:00-05:00,ONCY,neutral
955884.0,Mid-Day Market Update: Neovasc Jumps After Submitting Approval Application For Neovasc Reducer; EyeGate Pharmaceuticals Shares Plummet,2019-12-31 12:09:00-05:00,ONCY,positive
955885.0,"Mid-Morning Market Update: Markets Mostly Flat; Seadrill Reports 3-Year, $199M Middle East Contract",2019-12-31 10:20:00-05:00,ONCY,neutral
955886.0,15 Stocks Moving in Tuesday's Pre-Market Session,2019-12-31 07:31:00-05:00,ONCY,neutral
955887.0,55 Biggest Movers From Yesterday,2019-12-31 04:21:00-05:00,ONCY,neutral
955888.0,32 Stocks Moving In Monday's Mid-Day Session,2019-12-30 12:13:00-05:00,ONCY,neutral
955889.0,"Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus",2019-12-29 18:38:00-05:00,ONCY,neutral
955890.0,46 Stocks Moving In Friday's Mid-Day Session,2019-12-27 12:05:00-05:00,ONCY,neutral
955891.0,31 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-12-27 08:13:00-05:00,ONCY,neutral
955892.0,"The Daily Biotech Pulse: Flexion Receives FDA Nod For Zilretta Label Expansion, Astellas Goes Shopping",2019-12-27 07:59:00-05:00,ONCY,neutral
955893.0,28 Stocks Moving in Friday's Pre-Market Session,2019-12-27 07:47:00-05:00,ONCY,neutral
955894.0,Oncolytics Biotech shares are trading higher on more than triple average volume. Not currently seen any news to justify the price action.,2019-12-26 15:47:00-05:00,ONCY,positive
955895.0,"The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut",2019-11-08 08:14:00-05:00,ONCY,neutral
955896.0,"The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight",2019-11-03 10:51:00-05:00,ONCY,neutral
955897.0,17 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-11-01 08:21:00-04:00,ONCY,neutral
955898.0,"The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo",2019-10-03 07:34:00-04:00,ONCY,negative
955899.0,Stocks That Hit 52-Week Lows On Wednesday,2019-10-02 10:55:00-04:00,ONCY,negative
955900.0,"The Daily Biotech Pulse: J&J Settles Ohio Opioid Lawsuit, Teligent Explores Options For Certain Assets, Novartis Reports Cosentyx Data",2019-10-02 07:17:00-04:00,ONCY,positive
955901.0,26 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-08-15 08:42:00-04:00,ONCY,neutral
955902.0,"The Daily Biotech Pulse: Mallinkckrodt's Terlipressin, Deciphera Offering, Sellas Reboots On Earnings",2019-08-15 07:45:00-04:00,ONCY,neutral
955903.0,32 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-08-14 08:50:00-04:00,ONCY,neutral
955904.0,"The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering",2019-08-14 07:50:00-04:00,ONCY,negative
955905.0,Oncolytics Biotech shares are trading lower after the company reported Q2 earnings.,2019-08-14 07:13:00-04:00,ONCY,neutral
955906.0,Oncolytics Biotech shares are trading lower after the company reported Q2 earnings.,2019-08-13 16:36:00-04:00,ONCY,neutral
955907.0,Oncolytics Biotech Q2 EPS $(0.26) Up From $(0.27) YoY,2019-08-13 16:35:00-04:00,ONCY,neutral
955908.0,"The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout",2019-08-07 07:34:00-04:00,ONCY,neutral
955909.0,"The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering",2019-08-06 07:22:00-04:00,ONCY,positive
955910.0,New 52-Week Lows For Monday Morning,2019-08-05 13:16:00-04:00,ONCY,negative
955911.0,Stocks That Set New 52-Week Lows Friday Morning,2019-08-02 10:46:00-04:00,ONCY,negative
955912.0,Stocks that Reached Yearly Lows Thursday Morning,2019-08-01 11:09:00-04:00,ONCY,negative
955913.0,"The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings",2019-08-01 07:18:00-04:00,ONCY,negative
955914.0,New 52-Week Low Achievers For Wednesday Morning,2019-07-31 11:16:00-04:00,ONCY,negative
955915.0,"The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings",2019-07-30 07:00:00-04:00,ONCY,positive
955916.0,"Companies Which Will Be Presenting At LD Micro's 9th Annual Micro Invitational Tues., Jun. 4, 2019",2019-06-03 16:57:00-04:00,ONCY,neutral
955917.0,"The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails",2019-05-21 07:40:00-04:00,ONCY,negative
955918.0,Oncolytics Biotech Earlier Reported First Patient Treated In Co.'s AWARE-1 Window Of Opportunity Study Of Pelareorep In Breast Cancer,2019-04-08 07:55:00-04:00,ONCY,negative
955919.0,75 Biggest Movers From Yesterday,2019-03-01 04:55:00-05:00,ONCY,neutral
955920.0,"The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial",2018-12-21 07:58:00-05:00,ONCY,neutral
955921.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018",2018-12-19 12:43:00-05:00,ONCY,negative
955922.0,"The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas",2018-12-19 07:46:00-05:00,ONCY,positive
955923.0,"The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan",2018-12-18 08:00:00-05:00,ONCY,positive
955924.0,52 Biggest Movers From Yesterday,2018-12-13 04:54:00-05:00,ONCY,neutral
955925.0,"Oncolytics Biotech Announces First Patient Treated In Study Combining Pelareorep, Carfilzomib And The Checkpoint Inhibitor Opdivo In Multiple Myeloma",2018-12-12 07:18:00-05:00,ONCY,negative
955926.0,"The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings",2018-12-11 08:22:00-05:00,ONCY,neutral
955927.0,"Stocks Which Set New 52-Week Low The Last Trading Session, Fri., Dec. 7, 2018",2018-12-10 11:01:00-05:00,ONCY,negative
955928.0,"Stocks Which Set New 52-Week Low Yesterday Tues., Nov. 27, 2018",2018-11-28 11:54:00-05:00,ONCY,negative
955929.0,"Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 26, 2018",2018-11-27 11:26:00-05:00,ONCY,negative
955930.0,"The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial",2018-11-27 07:32:00-05:00,ONCY,negative
955931.0,"Oncolytics Reports First Patient Treated In Phase 2 Study Combining Pelareorep, Keytruda In Advance Pancreatic Cancer",2018-11-26 08:05:00-05:00,ONCY,negative
955932.0,"The Daily Biotech Pulse: Mallinckrodt Faces FDA Panel, Reshape's Earnings, Vapotherm To Debut",2018-11-14 08:17:00-05:00,ONCY,neutral
955933.0,Oncolytics Biotech Q3 EPS $(0.20),2018-11-12 07:01:00-05:00,ONCY,neutral
955934.0,"Stocks Which Set New 52-Week Low Yesterday, October 29th",2018-10-30 12:40:00-04:00,ONCY,negative
955935.0,"The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default",2018-10-26 08:17:00-04:00,ONCY,negative
955936.0,"The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price",2018-10-25 08:03:00-04:00,ONCY,negative
955937.0,Oncolytics Biotech Up to $30M At-The-Market Facility,2018-10-25 03:56:00-04:00,ONCY,neutral
955938.0,11 Stocks That Moved From ESMO 2018,2018-10-22 13:39:00-04:00,ONCY,neutral
955939.0,Oncolytics Biotech Highlights Presentation Of Clinical Trial Results For Pelareorep In Patients With KRAS Mutant Metastatic Colorectal Cancer At European Society for Medical Oncology,2018-10-22 07:13:00-04:00,ONCY,negative
955940.0,"The Daily Biotech Pulse: Enzo's Q4 Loss, Sanofi's Positive Trial Results, ImmunoCellular To Delist",2018-10-16 08:52:00-04:00,ONCY,positive
955941.0,"Stocks Which Set New 52-Week Low Yesterday, October 10th",2018-10-11 09:11:00-04:00,ONCY,negative
955942.0,"The Daily Biotech Pulse: Clinical Hold Lifted Off Crispr's Gene-Edited Therapy, Endra To Offer Shares",2018-10-11 07:39:00-04:00,ONCY,positive
955943.0,Oncolytics Biotech Highlights Publication Of Clinical Results For Pelareorep In Abstract For ESMO 2018,2018-10-11 07:10:00-04:00,ONCY,neutral
955944.0,"Stocks Which Set New 52-Week Low Yesterday, October 9th",2018-10-10 11:01:00-04:00,ONCY,negative
955945.0,"The Daily Biotech Pulse: Novartis Blood Disorder Drug Improves Patient Outcomes, Audentes To Offer Shares",2018-10-10 07:56:00-04:00,ONCY,positive
955946.0,"The Daily Biotech Pulse: Affimed's Cancer Drug Placed On Clinical Hold, Celgene's Positive Scalp Psoriasis Trial",2018-10-09 08:03:00-04:00,ONCY,negative
955947.0,Oncolytics Biotech Announces Publication Demonstrating That Intravenously Delivered Oncolytic Viruses Effectively Target Tumors,2018-10-02 07:03:00-04:00,ONCY,positive
955948.0,"Oncolytics Biotech Enters Common Stock Purchase Agreement For Up To US$26M With Lincoln Park Capital, LLC",2018-09-28 08:38:00-04:00,ONCY,positive
955949.0,REMINDER: Oncolytics Biotech Currently Holding a Business Update,2018-09-20 09:14:00-04:00,ONCY,neutral
955950.0,Oncolytics Biotech Announces a Second Study in Multiple Myeloma,2018-09-17 07:06:00-04:00,ONCY,neutral
955951.0,44 Biggest Movers From Friday,2018-09-17 05:10:00-04:00,ONCY,neutral
955952.0,32 Stocks Moving In Friday's Mid-Day Session,2018-09-14 12:31:00-04:00,ONCY,neutral
955953.0,46 Biggest Movers From Yesterday,2018-09-14 04:40:00-04:00,ONCY,neutral
955954.0,36 Stocks Moving In Thursday's Mid-Day Session,2018-09-13 13:12:00-04:00,ONCY,neutral
955955.0,"Stocks Which Set New 52-Week Low Yesterday, September 5th",2018-09-06 08:49:00-04:00,ONCY,negative
955956.0,"The Daily Biotech Pulse: Novartis Divestment, Eyepoint's Drug Gets Coverage, Spectrum's Robust Data",2018-09-06 08:28:00-04:00,ONCY,positive
955957.0,Oncolytics Biotech Announces Master Supply Agreement With F. Hoffmann-La Roche To Supply Tecentriq For Use In Co.'s Clinical Development Program,2018-09-06 07:09:00-04:00,ONCY,positive
955958.0,"The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results",2018-09-05 08:28:00-04:00,ONCY,positive
955959.0,61 Biggest Movers From Friday,2018-08-13 06:43:00-04:00,ONCY,neutral
955960.0,"The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel",2018-08-07 08:23:00-04:00,ONCY,negative
955961.0,Oncolytics Biotech Reports Q2 EPS $(0.27) vs $(0.32) In Prior Year Period,2018-08-03 07:04:00-04:00,ONCY,neutral
955962.0,28 Stocks Moving In Monday's Pre-Market Session,2018-07-02 08:06:00-04:00,ONCY,neutral
955963.0,24 Stocks Moving In Friday's Pre-Market Session,2018-06-29 08:04:00-04:00,ONCY,neutral
955964.0,"Benzinga's Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut",2018-06-28 08:26:00-04:00,ONCY,positive
955965.0,"Benzinga's Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading",2018-06-27 08:14:00-04:00,ONCY,negative
955966.0,"Benzinga's Daily Biotech Pulse: Epidiolex, Roche's Influenza Drug Gets Priority Review Status, Xeris Jumps On Positive Trial Results",2018-06-26 08:34:00-04:00,ONCY,positive
955967.0,"Benzinga's Daily Biotech Pulse: Johnson & Johnson to Dispose Sterilization Products Business, Mixed Results From Protesostasis' Cystic Fibrosis Study",2018-06-07 07:58:00-04:00,ONCY,neutral
955968.0,"Benzinga's Daily Biotech Pulse: Vascular Biogenics Soars On Positive Platform Data, Axovant Licenses Parkinson's Candidate",2018-06-06 08:38:00-04:00,ONCY,positive
955969.0,45 Biggest Movers From Yesterday,2018-06-06 04:35:00-04:00,ONCY,neutral
955970.0,Oncolytics Biotech Prices Offer Of ~1.37M Common Shares At $5.83/Share,2018-06-01 09:13:00-04:00,ONCY,positive
955971.0,"Oncolytics Biotech Reports Shares Were Approved For Listing On Nasdaq Starting Jun. 1, 2018, Will Trade Under Symbol 'ONCY'",2018-06-01 07:43:00-04:00,ONCY,positive
955972.0,Oncolytics Biotech Announces Phase 1b Study in Advanced Pancreatic Cancer is Now Active,2015-10-20 06:41:00-04:00,ONCY,negative
955973.0,Oncoloytics Biotech Announces Data From Multiple Myeloma Clinical Study,2015-09-25 06:32:00-04:00,ONCY,neutral
955974.0,Oncolytics Biotech Collaborators to Present Survival Data from REO 016 Study in NCLC at IASLC,2015-08-27 06:33:00-04:00,ONCY,neutral
955975.0,Oncolytics Biotech Collaborators Present Final Data from REO 017 Clinical Study in Pancreatic Cancer,2015-07-06 06:32:00-04:00,ONCY,negative
955976.0,US Stock Futures Signal Lower Start On Wall Street,2015-06-15 07:15:00-04:00,ONCY,negative
955977.0,Oncolytics Announces Collaborators to Present REOLYSIN Preclinical Data at ICOVT,2015-06-15 06:32:00-04:00,ONCY,neutral
955978.0,Oncolytics Reports Update on Plannede Registration Program for REOLYSIN,2015-06-08 16:02:00-04:00,ONCY,neutral
955979.0,US Stock Futures Surge Ahead Of Housing-Starts Data,2015-05-19 07:12:00-04:00,ONCY,neutral
955980.0,Oncolytics Biotech Submits iNDA to FDA for Phase 1 Study in Pediatric Patients with Brain Tumors,2015-05-19 06:33:00-04:00,ONCY,neutral
955981.0,"Oncolytics Biotech Q1 EPS -$0.04 CAD, No Estimates",2015-05-07 06:39:00-04:00,ONCY,negative
955982.0,UPDATE: Oncolytics Biotech Announces Receipt of Orphan Drug Designation from FDA for Reolysin for Gastric Cancer,2015-05-06 06:39:00-04:00,ONCY,negative
955983.0,FDA Site Shows Oncolytics Reolysin for Gastric Cancer Designated for Orphan Status,2015-05-05 10:07:00-04:00,ONCY,negative
955984.0,Oncolytics Biotech Shares Rise 12% Premarket as Company Receives Orphan Drug Status from EMA for Pancreatic Cancer,2015-04-29 07:39:00-04:00,ONCY,negative
955985.0,Oncolytics Collaborators Present REOLYSIN Preclinical Data at AACR Annual Meeting,2015-04-20 06:39:00-04:00,ONCY,neutral
955986.0,US Stock Futures Up Ahead Of Consumer Credit Report,2015-04-07 07:19:00-04:00,ONCY,positive
955987.0,Oncolytics Biotech Inc. Announces Filing for Orphan Drug Designation with the U.S. FDA for Gastric Cancer,2015-04-07 06:30:00-04:00,ONCY,negative
955988.0,Oncolytics Also Being Mentioned Now for Potential Mention on 60 Minutes Brain Cancer Segment,2015-03-27 10:26:00-04:00,ONCY,negative
955989.0,Oncolytics Biotech Receives Orphan Drug Status from EMA for Ovarian Cancer,2015-03-25 06:31:00-04:00,ONCY,negative
955990.0,Oncolytics Biotech® Inc. Collaborators Present Preclinical Data on the Combination of REOLYSIN and Radiotherapy in Melanoma,2015-03-05 06:33:00-05:00,ONCY,neutral
955991.0,Morning Market Gainers,2015-03-03 09:52:00-05:00,ONCY,neutral
955992.0,Oncolytics Biotech Receives FDA Orphan Drug Designation for Pancreatic Cancer for REOLYSIN for Treatment of Primary Peritoneal Cancers; Shares Rise 10% Premarket,2015-03-03 07:09:00-05:00,ONCY,negative
955993.0,Oncolytics Biotech Receives FDA Orphan Drug Designationfor Pancreatic Cancer,2015-02-17 06:30:00-05:00,ONCY,negative
955994.0,The FDA Just Gave Oncolytics Biotech A Big Bump,2015-02-11 14:36:00-05:00,ONCY,neutral
955995.0,Morning Market Gainers,2015-02-11 09:48:00-05:00,ONCY,neutral
955996.0,"Morning-Market Movers Led By Oncolytics Biotech, Rite Aid & Pepsi",2015-02-11 09:32:00-05:00,ONCY,neutral
955997.0,US Stock Futures Edge Lower Ahead Of Earnings,2015-02-11 07:26:00-05:00,ONCY,negative
955998.0,UPDATE: Oncolytics Biotech Receives FDA Orphan Drug Designation for Ovarian Cancer,2015-02-11 06:53:00-05:00,ONCY,negative
955999.0,Oncolytics Receives FDA Orphan Designation for Reolysin for Treatment of Ovarian Cancer,2015-02-10 15:09:00-05:00,ONCY,negative
956000.0,Stifel Terminates Coverage On Oncolytics Biotech Due To Reallocation Of Resources,2015-02-09 08:35:00-05:00,ONCY,neutral
956001.0,US Stock Futures Up Ahead Of Existing-Home Sales Data,2014-12-22 07:16:00-05:00,ONCY,neutral
956002.0,Oncolytics Biotech Files for Orphan Designation with the EMA for REOLYSIN for Treatment of Pancreatic and Ovarian Cancers,2014-12-22 06:38:00-05:00,ONCY,neutral
956003.0,"US Stock Futures Up Ahead Of Auto Sales, Construction Spending Data",2014-12-02 07:02:00-05:00,ONCY,neutral
956004.0,Oncolytics Biotech Files for Orphan Drug Designation with FDA for REOLYSIN,2014-12-02 06:32:00-05:00,ONCY,neutral
956005.0,Oncolytics Biotech Receives Nasdaq Notice of Deficiency,2014-11-04 17:03:00-05:00,ONCY,neutral
956006.0,Oncolytics Biotech Reports Amendment to Common Share Purchase Deal with Lincoln Park Capital Fund: Will Issue ~146.4K Shares to LPC,2014-10-20 17:35:00-04:00,ONCY,positive
956007.0,Stocks Hitting 52-Week Lows,2014-09-17 10:07:00-04:00,ONCY,negative
956008.0,Morning Market Losers ,2014-09-17 09:48:00-04:00,ONCY,negative
956009.0,"Oncolytics Reports Overall, KRAS-Mutated Patient Data from US Randomized Phase 2 Pancreatic Cancer Study",2014-09-16 17:08:00-04:00,ONCY,negative
956010.0,Oncolytics Biotech Completes Patient Enrollment in Randomized Phase 2 Ovarian Cancer Study ,2014-09-03 06:32:00-04:00,ONCY,negative
956011.0,Oncolytics Biotech Files for Up to C$150 Mixed Shelf ,2014-07-25 14:32:00-04:00,ONCY,neutral
956012.0,Oncolytics Biotech Completes Patient Enrollment In US Randomized Phase II Pancreatic Cancer Study,2014-07-08 06:31:00-04:00,ONCY,negative
956013.0,Ophthotech Mega Million Deal With Novartis; Oncolytics Biotech Brain Cancer Trial Positive Data; Tarena International Solid Results,2014-05-20 09:40:00-04:00,ONCY,negative
956014.0,Oncolytics Collaborators to Present Positive Brain Cancer Clinical Trial Data at ASCO,2014-05-20 06:31:00-04:00,ONCY,negative
956015.0,Oncolytics Biotech Reports Q1 EPS of C$(0.06) vs C$(0.07) Est,2014-05-08 06:48:00-04:00,ONCY,neutral
956016.0,Oncolytics Collaborators Present Head and Neck Cancer Biomarker Preclinical Research at UK Oncolytic Virus Conference ,2014-04-14 06:37:00-04:00,ONCY,negative
956017.0,Oncolytics Collaborators Present Translational Brain Cancer Clinical Data and Immunomodulatory Preclinical Research ,2014-04-11 06:33:00-04:00,ONCY,negative
956018.0,US Stock Futures Drop; Alcoa Earnings In Focus,2014-04-08 07:25:00-04:00,ONCY,negative
956019.0,Oncolytics Biotech Announces Encouraging Data from REO 018 Randomized Study of REOLYSIN in Head and Neck Cancers ,2014-04-08 06:39:00-04:00,ONCY,positive
956020.0,Oncolytics Collaborators to Present Preclinical Research in Multiple Myeloma and Melanoma at AACR 2014 ,2014-04-07 06:33:00-04:00,ONCY,neutral
956021.0,Oncolytics Shares Move Higher; May be in Sympathy with Endocyte,2014-03-21 09:35:00-04:00,ONCY,positive
956022.0,"Stocks to Watch for March 21, 2014",2014-03-21 09:00:00-04:00,ONCY,neutral
956023.0,US Stock Futures Up Ahead Of Jobless Claims Data,2013-11-21 06:59:00-05:00,ONCY,neutral
956024.0,Oncolytics Biotech Announces Positive Top-Line Data from REO 018 Randomized Study of REOLYSIN,2013-11-21 06:28:00-05:00,ONCY,positive
956025.0,Oncolytics Announces Positive Phase 2 REOLYSIN Data,2013-10-28 06:36:00-04:00,ONCY,positive
956026.0,Oncolytics Announces Progression Free Survival Data for Phase 2 REOLYSIN Study ,2013-10-22 06:42:00-04:00,ONCY,positive
956027.0,Morning Market Movers ,2013-10-04 10:02:00-04:00,ONCY,neutral
956028.0,"Needham Initiates Coverage on Oncolytics Biotech, Inc. at Buy, Announces $8.00 PT",2013-09-12 16:27:00-04:00,ONCY,neutral
956029.0,Adam Feuerstein Tweet on Oncolytics: '$ONCY up 29% despite Reolysin lung cancer study update in which ORR DECREASED from 43% in March to 40% today',2013-09-09 11:34:00-04:00,ONCY,positive
956030.0,US Stock Futures Up Ahead Of Consumer Credit Data,2013-09-09 07:15:00-04:00,ONCY,positive
956031.0,Oncolytics Biotech Announces Positive Final Tumour Response Data for US Phase 2 Study of REOLYSIN in Squamous Cell Lung Cancer ,2013-09-09 06:33:00-04:00,ONCY,negative
956032.0,Afternoon Market Gainers,2013-06-25 12:42:00-04:00,ONCY,neutral
956033.0,Oncolytics Announces First Stage of Metastatic Melanoma Phase 2 Trial Meets Primary Endpoint,2013-05-22 06:41:00-04:00,ONCY,neutral
956034.0,Oncolytics Phase 2 Study of REOLYSIN Meets Primary Endpoint in Squamous Cell Lung Cancer ,2013-03-28 06:32:00-04:00,ONCY,negative
956035.0,A Peek Into The Market Before The Trading Starts,2013-03-05 07:11:00-05:00,ONCY,neutral
956036.0,Oncolytics Completes Enrollment for US Phase 2 Study of REOLYSIN in Non-Small Cell Lung Cancer ,2013-03-05 06:45:00-05:00,ONCY,negative
956037.0,"Piper Jaffray Initiated Coverage on Oncolytics Biotech, Inc. at Overweight, Announced $6.00 PT",2013-03-04 10:01:00-05:00,ONCY,negative
956038.0,Benzinga's Top Initiations,2013-03-04 07:26:00-05:00,ONCY,positive
956039.0,Oncolytics Closes Offering of 8M Shares at $4/Share for Gross Proceeds of $32M,2013-02-25 11:54:00-05:00,ONCY,negative
956040.0,"Oncolytics Shares Resume Trading, Now Down 12+%",2013-02-20 09:45:00-05:00,ONCY,positive
956041.0,Oncolytics Biotech Shares to Resume Trade at 9:45AM EST,2013-02-20 09:13:00-05:00,ONCY,positive
956042.0,Oncyolytics Halted Following Announcing Pricing of 8M Shares at $4/Share,2013-02-20 09:02:00-05:00,ONCY,positive
956043.0,A Peek Into The Market Before The Trading Starts,2013-02-08 07:23:00-05:00,ONCY,neutral
956044.0,Oncolytics Biotech Announces Additional Positive Phase 2 REOLSYIN Clinical Trial Data ,2013-02-08 06:52:00-05:00,ONCY,positive
956045.0,UPDATE: Bloom Burton & Co Downgrades Oncolytics Biotech to Hold on Valuation  ,2012-12-18 08:21:00-05:00,ONCY,neutral
956046.0,"Bloom Burton & Co. Downgrades Oncolytics Biotech, Inc. to Hold",2012-12-18 07:46:00-05:00,ONCY,neutral
956047.0,Morning Market Movers,2012-12-13 09:56:00-05:00,ONCY,neutral
956048.0,A Peek Into The Market Before The Trading Starts,2012-12-13 07:21:00-05:00,ONCY,neutral
956049.0,Oncolytics Announces Positive Top Line REOLYSIN Data for First Endpoint in Randomized Phase III Study in Head and Neck Cancers ,2012-12-13 06:34:00-05:00,ONCY,positive
956050.0,Stonegate Securities Suspends Coverage on Oncolytics Biotech,2012-10-08 14:12:00-04:00,ONCY,positive
956051.0,Oncolytics Biotech  Announces Dr. Alan J. Tuchman as Chief Medical Officer ,2012-09-28 06:35:00-04:00,ONCY,neutral
956052.0,Oncolytics Biotech Meets Primary Endpoint for First Stage of U.S. Phase 2 Squamous Cell Lung Cancer Clinical Trial ,2012-09-13 07:01:00-04:00,ONCY,negative
956053.0,"Bloom Burton & Co.  Maintains Oncolytics Biotech at Buy, Lowers PT to $4",2012-09-12 12:41:00-04:00,ONCY,negative
956054.0,Stocks Hitting 52-Week Lows,2012-09-12 11:50:00-04:00,ONCY,negative
956055.0,Oncolytics Biotech Resumes Trading,2012-09-12 07:33:00-04:00,ONCY,neutral
956056.0,Oncolytics Biotech Provides Update on Phase III Study of REOLYSIN in Head and Neck Cancers,2012-09-12 07:06:00-04:00,ONCY,neutral
956057.0,UPDATE: Stifel Nicolaus Initiates Oncolytics Ciotech at Buy with $6 PT on Reolysin Cancer Focus  ,2012-08-30 13:01:00-04:00,ONCY,negative
956058.0,"Stifel Nicolaus Initiates Coverage on Oncolytics Biotech at Buy, Announces PT of $6",2012-08-30 08:04:00-04:00,ONCY,neutral
956059.0,Oncolytics Biotech Completes Patient Enrollment in US Phase I Clinical Trial Investigating REOLYSIN in Combination with FOLFIRI in Patients with Colorectal Cancer,2012-08-16 07:13:00-04:00,ONCY,negative
956060.0,Oncolytics Biotech Completes Patient Enrollment in UK Phase I Clinical Trial Investigating REOLYSIN in Combination with Cyclophosphamide in Patients with Advanced Malignances,2012-08-16 07:12:00-04:00,ONCY,positive
956061.0,Edison Investment Research: Oncolytics Biotech's Pending Outcome,2012-07-06 08:17:00-04:00,ONCY,neutral
956062.0,Oncolytics Biotech Inc. Enters into Sponsorship Agreement with NCIC CTG for Randomized Phase II Study in Advanced and Metastatic Breast Cancers ,2012-06-21 07:17:00-04:00,ONCY,positive
956063.0,Oncolytics Biotech Inc. Announces Publication of Translational Clinical Trial Results in Science Translational Medicine ,2012-06-13 14:03:00-04:00,ONCY,neutral
956064.0,"Option Alert: Oncolytics Biotech September Call Volume at 2,232% of Average; Currently $3.51",2012-06-13 11:00:00-04:00,ONCY,positive
956065.0,"Option Alert: Oncolytics Biotech September 5 Call; Block Trade: 5,000 Contracts; Currently $3.52",2012-06-12 12:58:00-04:00,ONCY,negative
956066.0,A Peek Into The Market Before The Trading Starts,2012-06-05 07:26:00-04:00,ONCY,neutral
956067.0,Oncolytics Biotech Inc. Enters into Sponsorship Agreement with NCIC CTG for Randomized Phase II Study in Non-Small Cell Lung Cancer ,2012-06-05 07:02:00-04:00,ONCY,negative
956068.0,Oncolytics Biotech Completes Enrollment in First Stage of Phase III Study in Head and Neck Cancers ,2012-04-02 07:09:00-04:00,ONCY,neutral
956069.0,Oncolytics Biotech Enters into Sponsorship Agreement with NCIC CTG for Randomized Phase II Study in Prostate Cancer  ,2012-02-21 07:02:00-05:00,ONCY,negative
956070.0,Morning Market Movers,2012-01-30 10:01:00-05:00,ONCY,neutral
956071.0,Oncolytics to Sell Shares at C$4.20 Each,2012-01-23 16:24:00-05:00,ONCY,positive
956072.0,Oncolytics Biotech Inc. Announces Phase 2 Clinical Trial of REOLYSIN,2011-12-02 07:01:00-05:00,ONCY,neutral
956073.0,Oncolytics Biotech Inc. Announces Positive Results of U.S. Phase 2 Clinical Trial Investigating REOLYSIN,2011-11-14 07:02:00-05:00,ONCY,positive
956074.0,Oncolytics Biotech Announces Appointment of Chief Medical Officer,2011-11-10 07:03:00-05:00,ONCY,neutral
956075.0,Oncolytics Biotech Announces Positive Publication of Preclinical Research on Synergistic Combination of Chemotherapy with Oncolytic Virotherapy  ,2011-08-02 07:27:00-04:00,ONCY,positive
956076.0,Oncolytics Biotech Collaborators Present Positive REOLYSIN Clinical Trial Results at the 14th World Conference on Lung Cancer ,2011-07-06 07:02:00-04:00,ONCY,negative
956077.0,Market Update,2011-07-05 09:36:00-04:00,ONCY,neutral
956078.0,A Peek Into The Market Before The Trading Starts,2011-07-05 07:36:00-04:00,ONCY,neutral
956079.0,Oncolytics Biotech Announces Appointment of Dr. George M. Gill as Chief Medical Officer  ,2011-07-05 07:07:00-04:00,ONCY,neutral
956080.0,Oncolytics Biotech Inc. Enters into Commercial Supply Agreement with SAFC  ,2011-05-11 07:34:00-04:00,ONCY,positive
956081.0,Oncolytics Biotech Inc. Announces Phase I Multiple Myeloma Cancer Study ,2011-05-10 07:39:00-04:00,ONCY,negative
956082.0,Oncolytics Biotech Announces Positive Data from Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer (ONCY),2011-04-20 07:35:00-04:00,ONCY,negative
956083.0,Wedbush Opens ONCY With Outperform,2011-04-13 06:09:00-04:00,ONCY,neutral
956084.0,"Mad Money Lightning Round OT: Cramer Is A Buyer Of EVR (ALXN, CEPH, GENZ, EVR, ONCY)",2011-04-04 20:08:00-04:00,ONCY,negative
956085.0,Oncolytics Biotech Inc. Completes Patient Enrollment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN in Combination with Paclitaxel and Carboplatin in Head and Neck Cancers ,2011-03-24 07:33:00-04:00,ONCY,neutral
956086.0,Oncolytics Biotech Reports FY10 Loss of $0.32 per share,2011-03-17 07:40:00-04:00,ONCY,neutral
956087.0,Oncolytics Biotech Inc. Reports 2010 EPS of $(0.32),2011-03-17 07:33:00-04:00,ONCY,neutral
956088.0,A Peek Into The Market Before The Trading Starts,2011-02-14 07:44:00-05:00,ONCY,neutral
956089.0,Oncolytics Biotech Meets Primary Endpoint for First Part of Phase 2 Pancreatic Cancer Clinical Trial ,2011-02-14 07:32:00-05:00,ONCY,negative
956090.0,Oncolytics Biotech Receives $6.8M from Exercise of Warrants ,2011-01-25 12:30:00-05:00,ONCY,neutral
956091.0,"Small Cap Stocks on the move:(CRDC),(WAVX),(MNI),(CXDC),(BSDM),(ONCY) more below",2011-01-18 22:44:00-05:00,ONCY,neutral
956092.0,Biotech's Brighter Corners,2010-12-08 12:45:00-05:00,ONCY,positive
956093.0,Oncolytics Biotech Inc. Announces Issuance of Key Patent,2010-09-28 07:37:00-04:00,ONCY,neutral
956094.0,"Early Volume Plays Among Those Valued Below $10 (BEAT, OREX, ONCY, CBRX)",2010-06-01 10:39:00-04:00,ONCY,positive
956095.0,"Benzinga’s Biggest Losers (BZ, ADSK, ILMN, CRM, NANO, ONCY)",2009-11-18 10:51:00-05:00,ONCY,negative
